Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Venus Remedies Limited (NSE: VENUSREM), ISIN INE411B01019 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
VENUSREM last traded at ₹1449.05 (+0.09%), with a 52-week range of ₹441.65 to ₹2044.30 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 41.76%, FIIs 3.14%, DIIs 0.74%, mutual funds 0.00%.
EquiSense Score (ECS): 84/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.